A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)

NCT01390441 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

100

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early by the Sponsor for business reasons.

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL: MK-8808
BIOLOGICAL: MabThera® (rituximab)
DRUG: Methotrexate
BIOLOGICAL: Rituxan® (rituximab)
DRUG: Methylprednisolone
DRUG: Acetaminophen
DRUG: Loratadine

Sponsor

Merck Sharp & Dohme LLC